Literature DB >> 25341583

Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.

Martee L Hensley1, Brigitte A Barrette, Klaus Baumann, David Gaffney, Anne L Hamilton, Jae-Weon Kim, Johanna U Maenpaa, Patricia Pautier, Nadeem Ahmad Siddiqui, Anneke M Westermann, Isabelle Ray-Coquard.   

Abstract

OBJECTIVES: The Gynecologic Cancer InterGroup aimed to provide an overview of uterine and ovarian leiomyosarcoma management.
METHODS: Published articles and author experience were used to draft management overview. The draft manuscript was circulated to international members of the Gynecologic Cancer InterGroup for review and comment, and appropriate revisions were made.
RESULTS: The approach to management of uterine and ovarian leiomyosarcoma management is reviewed.
CONCLUSIONS: Uterine and ovarian leiomyosarcomas are rare and aggressive cancers that require specialized expertise for optimal management.

Entities:  

Mesh:

Year:  2014        PMID: 25341583      PMCID: PMC4830912          DOI: 10.1097/IGC.0000000000000261

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  59 in total

1.  Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease.

Authors:  M H Einstein; R R Barakat; D S Chi; Y Sonoda; K M Alektiar; M L Hensley; N R Abu-Rustum
Journal:  Int J Gynecol Cancer       Date:  2007-11-06       Impact factor: 3.437

2.  Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.

Authors:  S W Bell; R L Kempson; M R Hendrickson
Journal:  Am J Surg Pathol       Date:  1994-06       Impact factor: 6.394

3.  Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Authors:  Martee L Hensley; John A Blessing; Robert Mannel; Peter G Rose
Journal:  Gynecol Oncol       Date:  2008-06       Impact factor: 5.482

4.  Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.

Authors:  B A Goff; L W Rice; D Fleischhacker; H G Muntz; S S Falkenberry; N Nikrui; A F Fuller
Journal:  Gynecol Oncol       Date:  1993-07       Impact factor: 5.482

5.  The risk of developing uterine sarcoma after tamoxifen use.

Authors:  O Lavie; O Barnett-Griness; S A Narod; G Rennert
Journal:  Int J Gynecol Cancer       Date:  2008 Mar-Apr       Impact factor: 3.437

6.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.

Authors:  Kelly D Gonzalez; Katie A Noltner; Carolyn H Buzin; Dongqing Gu; Cindy Y Wen-Fong; Vu Q Nguyen; Jennifer H Han; Katrina Lowstuter; Jeffrey Longmate; Steve S Sommer; Jeffrey N Weitzel
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

Authors:  N S Reed; C Mangioni; H Malmström; G Scarfone; A Poveda; S Pecorelli; S Tateo; M Franchi; J J Jobsen; C Coens; I Teodorovic; I Vergote; J B Vermorken
Journal:  Eur J Cancer       Date:  2008-04-02       Impact factor: 9.162

8.  Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group).

Authors:  H B Muss; B Bundy; P J DiSaia; H D Homesley; W C Fowler; W Creasman; E Yordan
Journal:  Cancer       Date:  1985-04-15       Impact factor: 6.860

9.  Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Authors:  Martee L Hensley; John A Blessing; Koen Degeest; Ovadia Abulafia; Peter G Rose; Howard D Homesley
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482

10.  Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems.

Authors:  Oliver Zivanovic; Mario M Leitao; Alexia Iasonos; Lindsay M Jacks; Qin Zhou; Nadeem R Abu-Rustum; Robert A Soslow; Margrit M Juretzka; Dennis S Chi; Richard R Barakat; Murray F Brennan; Martee L Hensley
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

View more
  15 in total

1.  Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

Authors:  Rebecca C Arend; Michael D Toboni; Allison M Montgomery; Robert A Burger; Alexander B Olawaiye; Bradley J Monk; Thomas J Herzog
Journal:  Oncologist       Date:  2018-08-23

Review 2.  PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?

Authors:  Michelle Lightfoot; Lauren Montemorano; Kristin Bixel
Journal:  Curr Oncol Rep       Date:  2020-02-17       Impact factor: 5.075

Review 3.  Gingival Leiomyosarcoma in a Young Woman: Case report and literature review.

Authors:  Massimo Viviano; Clelia Miracco; Guido Lorenzini; Gennaro Baldino; Serena Cocca
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10

4.  Genomic, Epigenomic, and Transcriptomic Profiling towards Identifying Omics Features and Specific Biomarkers That Distinguish Uterine Leiomyosarcoma and Leiomyoma at Molecular Levels.

Authors:  Tomoko Miyata; Kenzo Sonoda; Junko Tomikawa; Chiharu Tayama; Kohji Okamura; Kayoko Maehara; Hiroaki Kobayashi; Norio Wake; Kiyoko Kato; Kenichiro Hata; Kazuhiko Nakabayashi
Journal:  Sarcoma       Date:  2015-12-28

5.  Unusual indolent behavior of leiomyosarcoma of the vagina: Is observation a viable option?

Authors:  Ayatallah M Khafagy; Lauren S Prescott; Anais Malpica; Shannon N Westin
Journal:  Gynecol Oncol Rep       Date:  2017-06-12

6.  Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.

Authors:  Jeong Yeol Park; Jeong Won Lee; Hyun Ju Lee; Jong Jin Lee; Seung Hwan Moon; Seo Young Kang; Gi Jeong Cheon; Hyun Hoon Chung
Journal:  J Gynecol Oncol       Date:  2017-02-02       Impact factor: 4.401

Review 7.  Role of surgery in gynaecological sarcomas.

Authors:  Valentina Ghirardi; Nicolò Bizzarri; Francesco Guida; Carmine Vascone; Barbara Costantini; Giovanni Scambia; Anna Fagotti
Journal:  Oncotarget       Date:  2019-04-02

8.  Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.

Authors:  Elena Cojocaru; Githmi Palahepitiva Gamage; John Butler; Desmond P Barton; Khin Thway; Cyril Fisher; Christina Messiou; Aisha B Miah; Shane Zaidi; Spyridon Gennatas; Charlotte Benson; Paul Huang; Robin L Jones
Journal:  Gynecol Oncol Rep       Date:  2021-03-02

9.  Long-term Survival in a Patient with Recurrent Pulmonary Metastases from Uterine Leiomyosarcoma.

Authors:  Gwenalyn Garcia; Shiksha Kedia; Meekoo Dhar
Journal:  Cureus       Date:  2015-12-15

10.  Presurgical Identification of Uterine Smooth Muscle Malignancies through the Characteristic FDG Uptake Pattern on PET Scans.

Authors:  Kung-Chu Ho; Yu-Hua Dean Fang; Gigin Lin; Shir-Hwa Ueng; Tzu-I Wu; Chyong-Huey Lai; Ho-Yen Chueh; Angel Chao; Ting-Chang Chang; Tzu-Chen Yen
Journal:  Contrast Media Mol Imaging       Date:  2018-06-19       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.